Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia.

ABSTRACT: The impact of the revised Clinical and Laboratory Standards Institute interpretative criteria for cefepime in Enterobacteriaceae remains unclear. We applied the new breakpoint on 644 previously defined cefepime-susceptible Enterobacteriaceae isolates. We found no differences in mortality or microbiological failure, regardless of isolates being susceptible or cefepime-susceptible dose-dependent by current criteria.

SUBMITTER: Foong KS 

PROVIDER: S-EPMC6735685 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature